Learn about the impact of Proton Therapy on Prostate cancer patients, explained by Dr. Jason Efstathiou.

Jason Efstathiou, M.D., PhD, is a Professor of Radiation Oncology at Harvard Medical School and also serves as director of the Genitourinary Division in Radiation Oncology at the Massachusetts General Hospital, USA.

He recently presented the results of a phase three clinical trial comparing proton therapy and IMRT for patients with low- and intermediate-risk prostate cancer.

As patients explore treatment options for prostate cancer, understanding their long-term impact is essential. This trial showed that both treatment modalities provide high tumor control rates with similar patient-reported quality of life outcomes.

While the study suggests both options are effective, proton therapy remains a key part of modern radiation oncology with unique advantages. Ongoing innovations in proton delivery continue to refine its role, ensuring the best outcomes for the right patients.

Key Highlights: 
• (00:42) Proton vs IMRT: Key Findings from a Phase 3 Trial
• (02:14) Proton therapy in prostate cancer: Who may benefit most?
• (03:14) Proton therapy in prostate cancer: investing for a better future
• (04:31) The unique advantages of proton therapy
• (05:52) Other indications that should be investigated and stakeholders
• (08:01) Quality of proton therapy research

📚 Want to learn more about the future of proton therapy? Take a closer look here: https://www.iba-protontherapy.com/

Disclaimer: The statements of the healthcare professional included in this testimonial reflect only the speaker’s opinion and personal experience. They do not necessarily reflect the opinion of any institution with whom he is affiliated or IBA’s opinion.